Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × dacomitinib × Clear all

Carcinoma, Non-Small-Cell Lung

NCT04027647 2025-06-12

Phase 2 Study of Dacomitinib in NSCLC

Phase 2 Active not recruiting

118 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04946968 2025-06-11

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Phase 2 Active not recruiting

24 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04155541 2025-05-23

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

Completed

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06486142 2024-07-03

ERIS

Phase 3 Recruiting

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04511533 2024-04-05

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Phase 4 Completed

101 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01000025 2023-08-22

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Phase 3 Completed

720 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05271916 2023-04-19

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Phase 1/2 Recruiting

140 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04768491 2021-02-24

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Unknown

82 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04675008 2021-01-05

Central Nervous System(CNS) Efficacy of Dacomitinib

Phase 2 Unknown

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04339829 2020-04-09

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Phase 2 Unknown

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01918761 2019-12-30

Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

5 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00548093 2019-05-21

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Phase 2 Completed

66 enrolled 19 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01465802 2019-01-09

ARCHER 1042

Phase 2 Completed

236 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01858389 2017-07-18

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

41 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01360554 2017-05-24

ARCHER 1009

Phase 3 Completed

878 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01121575 2015-10-28

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Phase 1 Completed

70 enrolled 50 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00769067 2015-10-07

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Phase 2 Completed

188 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00971191 2012-06-22

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Phase 1 Terminated

22 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 2 Study of Dacomitinib in NSCLC

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

DELINOR

ERIS

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Central Nervous System(CNS) Efficacy of Dacomitinib

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

ARCHER 1042

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

ARCHER 1009

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804